CEO Bill Sibold hailed 2024 as a "transformational year" for Madrigal Pharmaceuticals, but Wall Street isn't as enthusiastic about the company's sales results.
Madrigal Pharmaceuticals announced its preliminary Q4 and full-year results. The company topped the official Wall Street estimates, but seems to have missed the so-called "whisper numbers." ...
Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full ...